Contribution of prolonged-release melatonin and anti-benzodiazepine campaigns to the reduction of benzodiazepine and Z-drugs consumption in nine European countries
about
Prevalence of sleep deficiency and use of hypnotic drugs in astronauts before, during, and after spaceflight: an observational studyCircadian rest-activity rhythms during benzodiazepine tapering covered by melatonin versus placebo add-on: data derived from a randomized clinical trialDid the new French pay-for-performance system modify benzodiazepine prescribing practices?Use of benzodiazepines and related drugs in Manitoba: a population-based studyMelatonin Therapy in Patients with Alzheimer's Disease.Withdrawing Benzodiazepines in Patients With Anxiety Disorders.Trends in incident use of benzodiazepines and Z-drugs in France from 2006 to 2012: a population-based study.Comorbidities and concurrent medications increasing the risk of adverse drug reactions: prevalence in French benzodiazepine users.Reducing Prescriptions of Long-Acting Benzodiazepine Drugs in Denmark: A Descriptive Analysis of Nationwide Prescriptions during a 10-Year Period.Insomnia disorder.Can clinical practice indicator relating to long-acting benzodiazepine use in the elderly be easily generated in a hospital setting?A systematic review of regulatory and educational interventions to reduce the burden associated with the prescriptions of sedative-hypnotics in adults treated for sleep disorders.Trends in utilization of benzodiazepine and Z-drugs in Israel.Changing Pattern of Sedative Use in Older Adults: A Population-Based Cohort Study.The effects of acute treatment with ramelteon, triazolam, and placebo on driving performance, cognitive function, and equilibrium function in healthy volunteers.
P2860
Q28395495-2A6E50B2-3487-42C3-939E-C68BAE5D31F2Q31136492-9703C3FE-A745-4987-B882-5411AF17CE5AQ33928145-1A13697D-A031-43C1-8CE3-E9A6B73FA79DQ34609374-B90B9CD1-6889-4680-A138-F4C180554EEAQ36335048-9AAAE79D-FA64-4C44-8D9E-E260EA50CD9FQ38687615-C596F8CF-D86B-4B95-B6D3-D5C3EE42E576Q39221733-7642E002-D307-477F-BAA7-448FBE5D83CBQ39882062-81D2488F-5DF2-4DF0-835B-B618FFD42FD2Q46101940-A58A84A9-6504-439C-A75E-FE5A9CA00FADQ46788076-528A9797-0626-4BA3-82B6-990309065735Q47214471-58C08D86-59DB-4076-B1D1-CBAB1455FD3CQ47642551-707C6054-5904-4B30-9EF3-80BB41E15A86Q47805456-43F4C815-32D8-49FF-8688-F534DA41F11AQ47851611-9F9FB037-FB30-4500-AC5F-C9642BA6D97BQ48006027-2D7CA750-A712-48B0-9CC0-5D983A2A3573
P2860
Contribution of prolonged-release melatonin and anti-benzodiazepine campaigns to the reduction of benzodiazepine and Z-drugs consumption in nine European countries
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Contribution of prolonged-rele ...... ion in nine European countries
@ast
Contribution of prolonged-rele ...... ion in nine European countries
@en
type
label
Contribution of prolonged-rele ...... ion in nine European countries
@ast
Contribution of prolonged-rele ...... ion in nine European countries
@en
prefLabel
Contribution of prolonged-rele ...... ion in nine European countries
@ast
Contribution of prolonged-rele ...... ion in nine European countries
@en
P2093
P2860
P1476
Contribution of prolonged-rele ...... ion in nine European countries
@en
P2093
Emilie Clay
Mondher Toumi
Nicholas Moore
P2860
P2888
P356
10.1007/S00228-012-1424-1
P577
2012-11-01T00:00:00Z